Tempus AI Juggles Debt Restructuring and Alzheimer Expansion as Losses Widen

Tempus AI restructures debt with convertible notes while entering neurodegenerative diagnostics; Q1 revenue surges 36% but GAAP net loss widens to $126M.

Tempus AI is pressing ahead on two fronts simultaneously—refinancing its balance sheet while pushing into the neurodegenerative diagnostics market—as the company navigates a period of rapid growth alongside deepening red ink.

The Chicago-based artificial intelligence healthcare firm announced plans to issue senior convertible notes due May 2032, using the proceeds to retire existing secured bank loans. The shift from secured debt to unsecured convertible instruments is expected to meaningfully reduce interest expenses. A portion of the capital will fund capped-call transactions designed to limit future equity dilution, giving management greater financial breathing room after an aggressive expansion phase.

Investors have greeted the debt restructuring with skepticism, however. Shares slid more than 7 percent in recent trading to €42.35, pushing the year-to-date decline to roughly 21 percent. The stock has struggled to gain traction despite a string of positive operational developments.

Revenue Surge Masks Persistent Losses

First-quarter 2026 results showed the company's top line growing at a blistering pace. Revenue climbed 36 percent year-over-year to $348.1 million, comfortably exceeding analyst expectations. The diagnostics core business drove much of that performance, contributing $261.1 million in revenue.

Within the oncology segment, testing volumes rose 28 percent. The minimal residual disease testing category posted an even more dramatic expansion, surging roughly 500 percent. Adjusted earnings per share came in at a loss of $0.13, narrower than many on Wall Street had braced for.

Yet the bottom line tells a different story. The GAAP net loss ballooned to nearly $126 million, widening from the prior-year period. On an operating basis, the company is edging closer to breakeven—adjusted EBITDA stood at just negative $2.8 million—but profitability remains elusive.

Entering Alzheimer's Diagnostics

In a strategic pivot beyond its oncology roots, Tempus AI has forged a partnership with Lucent Diagnostics to integrate blood-based Alzheimer's testing into clinical workflows. The collaboration aims to leverage the company's healthcare data operating system and generative AI capabilities to tailor laboratory tests more precisely to individual patients, improving early detection of neurodegenerative diseases.

The move into dementia diagnostics marks a significant expansion of Tempus's addressable market, which has historically centered on cancer research and treatment. Management sees the partnership as a natural extension of the company's AI-driven approach to precision medicine.

Outlook and Investor Focus

For the full year 2026, Tempus AI raised its revenue guidance to a range of $1.59 billion to $1.60 billion. While the revised forecast signals confidence in continued momentum, the upper end of the range sits at the lower boundary of what the market had been expecting.

All eyes now turn to the company's first investor day, scheduled for late May. Management is expected to lay out detailed plans for scaling its AI models and expanding into new clinical areas. The Alzheimer's partnership with Lucent Diagnostics is likely to feature prominently in those discussions, alongside the broader strategy for building a sustainable, profitable business around AI-powered medicine.